Modificaciones en las características de los ingresos hospitalarios por cirrosis descompensada en la era de los antivirales de acción directa frente al virus de la hepatitis C

Fraile López, Miguel; Franco, Lissa; Álvarez Navascués, Carmen; Varela, María; Cadahía, Valle; Torner, María; Gómez Outomuro, Ana; González-Diéguez, María Luisa; Rodríguez García, Manuel.
Rev. esp. enferm. dig ; 112(7): 538-544, jul. 2020. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-199941

Documentos relacionados

  1. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
  2. Bringing the Hepatitis C Virus to Life.
  3. Prospects for Long-Acting Treatments for Hepatitis C.
  4. Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatment.
  5. Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
  6. Hepatitis C associated to substance abuse: ever closer to a treatment without Interferon.
  7. Countering 'the moral science of biopolitics': Understanding hepatitis C treatment 'non-compliance' in the antiviral era.
  8. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments.
  9. Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study.
  10. Early initiation of glecaprevir/pibrentasvir after transplantation of HCV-viremic kidneys into HCV-negative recipients is associated with normalization in the altered inflammatory milieu.